George A. Eldridge, SEE REMARKS at Aerovate Therapeutics, Inc. (AVTE), sold 85 shares at $19.06 ($2K) on 2022-11-30, disclosed to the SEC on 2022-12-02.
Scheduled sale ($2k) by SEE REMARKS under a pre-arranged 10b5-1 plan. Pre-set trade — not a discretionary signal on the stock.
Negative factors outweigh the positive ones.
| Filing → |
| AVTE | SELL | 2024-04-03 | $780K | — | Filing → |
| AVTE | SELL | 2024-03-14 | $204K | — | Filing → |
| AVTE | SELL | 2024-03-11 | $736K | — | Filing → |